CAR-T Cell Therapy Shows Promise Against Progressive Multiple Sclerosis
A phase 1 trial targeting plasma cells in the CNS with anti-BCMA CAR-T therapy signals a potential breakthrough for untreatable progressive MS.
Summary
Progressive multiple sclerosis (PMS) has long resisted effective treatment, partly because plasma cells hidden within the central nervous system drive ongoing inflammation beyond the reach of standard B cell therapies. Researchers from Tongji Hospital treated five PMS patients with anti-BCMA CAR-T cell therapy — a precision immunotherapy already used in blood cancers — in a phase 1 trial. All five patients tolerated the treatment well, with only mild cytokine release syndrome and manageable blood count drops within 40 days. CAR-T cells expanded and remained active in cerebrospinal fluid, plasma cells in the CNS were depleted, and microglial activation — a marker of neuroinflammation — was reduced. These early results suggest anti-BCMA CAR-T therapy may reach immune targets that current MS drugs cannot.
Detailed Summary
Progressive multiple sclerosis is one of neurology's most frustrating frontiers. Unlike relapsing-remitting MS, PMS involves steady neurological decline driven by compartmentalized inflammation inside the CNS — particularly from plasma cells entrenched behind the blood-brain barrier. Standard therapies like CD20-targeting antibodies are largely unable to penetrate this immune sanctuary, leaving patients with few meaningful options.
This phase 1 clinical trial (NCT04561557) explored whether anti-BCMA CAR-T cell therapy — an engineered immune cell approach proven effective against plasma cell cancers like multiple myeloma — could tackle MS-driving plasma cells within the CNS itself. Five patients (one primary PMS, four secondary PMS) received the therapy and were monitored for safety and biological response.
The safety profile was encouraging. All patients experienced only grade 1 cytokine release syndrome, the mildest form of the most common CAR-T side effect. Blood count reductions of grade 3 or higher occurred but resolved within 40 days post-infusion — a manageable window compared to more severe CAR-T toxicities seen in oncology settings.
Biologically, the results were striking. CAR-T cells not only entered the cerebrospinal fluid but expanded there and showed reduced exhaustion signals, suggesting sustained activity. Plasma cell depletion was detected in CNS compartments, and microglial activation — a key driver of neurodegeneration in PMS — was attenuated. These mechanistic findings align with the hypothesis that targeting CNS-resident plasma cells could interrupt the smoldering inflammatory cycle underlying PMS.
Caveats are significant: this is a very small, early-phase study with no control group and short follow-up. Long-term clinical outcomes such as disability stabilization or reversal remain unconfirmed. Nonetheless, this work opens a credible new therapeutic avenue for a disease that desperately needs one, and warrants larger trials.
Key Findings
- Anti-BCMA CAR-T therapy was tolerated in all 5 PMS patients with only grade 1 cytokine release syndrome.
- CAR-T cells expanded and showed reduced exhaustion in cerebrospinal fluid, indicating CNS penetration and activity.
- Plasma cell depletion was detected within CNS compartments, a target unreachable by standard CD20 antibody therapies.
- Microglial activation — a neuroinflammation biomarker — was attenuated following treatment.
- All grade ≥3 blood count reductions resolved within 40 days post-infusion.
Methodology
This was a phase 1 clinical trial (NCT04561557) enrolling five patients with progressive MS (1 primary, 4 secondary). Patients received anti-BCMA CAR-T cell infusions and were assessed for safety, CAR-T expansion in CSF, CNS plasma cell depletion, and microglial activation markers. No control group was included given the early-phase design.
Study Limitations
The study enrolled only five patients with no control arm, making it impossible to draw conclusions about clinical efficacy or long-term outcomes. Follow-up duration is not specified in the abstract, limiting assessment of durability. Broader applicability, optimal dosing, and long-term safety require investigation in larger, controlled trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: